David Arkowitz insider trades

Open-market stock purchases and sales by David Arkowitz, Director at iBio, Inc, from SEC Form 4 filings since Feb 24, 2010.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -33%.

Recent trades

DateStockTradeValue
Nov 20, 2025IBIO iBio, IncBought (not open market)—

Companies traded

  • IBIO iBio, Inc: 1 buy, last Nov 20, 2025
  • KANT Kineta, Inc./de: other filings, last Jun 30, 2025
  • KA Kineta, Inc./de: other filings, last Sep 4, 2024
  • MCRB Seres Therapeutics, Inc: 2 sales, last Feb 16, 2024
  • FSTX F-star Therapeutics, Inc: other filings, last Mar 8, 2023
  • YMTX Yumanity Therapeutics, Inc: other filings, last Jun 2, 2021
  • FLXN Flexion Therapeutics Inc: 4 buys, 5 sales, last May 10, 2021
  • SBPH F-star Therapeutics, Inc: 2 buys, last Nov 19, 2020
  • PTI Proteostasis Therapeutics, Inc: other filings, last Jun 29, 2020
  • AMAG Amag Pharmaceuticals Inc: 3 buys, 3 sales, last May 31, 2011

Get free alerts when David Arkowitz files a new trade →